The early stage detection of cancer increases the optimal results of therapies and subsequently the survival rate of cancer patients. However, the early detection of cancer has remained inadequate for two main reasons:
- The existing tools and biomarkers lack a high sensitivity and specificity to be served as an effective diagnostic test in both asymptomatic and symptomatic cases.
- The available methods for early screening are often very expensive and require much care and expertise to perform and interpret the results.
Several studies have indicated that DNA repair deficiency and accumulation of DNA damage (Genomic Instability) represents a powerful general biomarker for the early detection of cancer. These effects are not only limited to the cancerous cells and local tissues but also reflected in peripheral blood cells of the cancer patients, independent of their cancer type. Taking advantage of the peripheral blood cells as a mirror of changes within the body of the cancer patients, these cells are providing a source of sensitive biomarker for early detection of all types of cancer.
4D Lifetec has developed the algorithmically based, highly standardized assay called 4D Lifetest™ that offers an outstanding performance results based on Single Cell Gel Electrophoresis.
The 4D Lifetest™ has passed successfully the preclinical phase including standardization and analytical validation of several types of cancer which documents 4D Lifetest™ as a versatile, precise and reproducible assay with a high-throughput capability.
Clinical Study - Phase I
4D Lifetest™ is now ready to market and therefore we started clinical studies on four most common cancer types including; Breast, Lung, Prostate and Colon cancer. In phase one up to 400 symptomatic patients will be tested in different leading cancer centers of Switzerland.
For personalised Lung and Breast Cancer Detection - Clinical Study of 4D Lifetest™ LC and BC:
St. Clara Hospital, Basel (Switzerland) under supervision of PD Dr. med. Bettina Wölnerhanssen, Head of St. Clara Research Ltd.
For personalised Prostate Cancer Detection - Clinical Study of 4D Lifetest™ PC:
Cantonal Hospital of St. Gallen (Switzerland) under the supervision of PD Dr. med. Daniel Engeler, Assistant Chief Doctor for Urology and Dr. Reinhard Maier, Operational Head of Clinical Trial Unit (CTU, Cantonal Hospital St. Gallen).
All our clinical trials are supported by SAKK Bern.
These studies will allow us to establish the necessary criteria’s for future clinical studies to establish 4D Lifetest™ as a universal screening assay for the early detection of cancer in asymptomatic patients.